Journal Article Practice Guideline Systematic Review Ppublish 29 citations
PubMed: 38498792 DOI: 10.1200/JCO.24.00032
Vaccination of Adults With Cancer: ASCO Guideline.
J Clin Oncol 42(14):1699-1721
Authors: Mini Kamboj, Kari Bohlke, Deana M Baptiste, Kieron Dunleavy, Abbey Fueger, Lee Jones, Amar H Kelkar, Lisa Y Law, Kristine B LeFebvre, Per Ljungman, Eric D Miller, Larissa A Meyer, Heather N Moore, Heloisa P Soares, Randy A Taplitz, Edom S Woldetsadik, Elise C Kohn
Affiliations
- Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
- American Society of Clinical Oncology, Alexandria, VA.
- American Cancer Society, Atlanta, GA.
- MedStar Georgetown University Hospital, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
- The Leukemia and Lymphoma Society, Rye Brook, NY.
- Fight Colorectal Cancer, Arlington, VA.
- Harvard Medical School, Dana Farber Cancer Institute, Boston, MA.
- Kaiser Permanente, Roseville, CA.
- Oncology Nursing Society, Pittsburgh, PA.
- Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.
- The Ohio State University Comprehensive Cancer Center, Columbus, OH.
- The University of Texas MD Anderson Cancer Center, Houston, TX.
- Duke University Medical Center, Durham, NC.
- Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.
- City of Hope Comprehensive Cancer Center, Duarte, CA.
- Addis Ababa University, Addis Ababa, Ethiopia.
- Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD.
Abstract
PURPOSE
To guide the vaccination of adults with solid tumors or hematologic malignancies.
METHODS
A systematic literature review identified systematic reviews, randomized controlled trials (RCTs), and nonrandomized studies on the efficacy and safety of vaccines used by adults with cancer or their household contacts. This review builds on a 2013 guideline by the Infectious Disease Society of America. PubMed and the Cochrane Library were searched from January 1, 2013, to February 16, 2023. ASCO convened an Expert Panel to review the evidence and formulate recommendations.
RESULTS
A total of 102 publications were included in the systematic review: 24 systematic reviews, 14 RCTs, and 64 nonrandomized studies. The largest body of evidence addressed COVID-19 vaccines.
RECOMMENDATIONS
The goal of vaccination is to limit the severity of infection and prevent infection where feasible. Optimizing vaccination status should be considered a key element in the care of patients with cancer. This approach includes the documentation of vaccination status at the time of the first patient visit; timely provision of recommended vaccines; and appropriate revaccination after hematopoietic stem-cell transplantation, chimeric antigen receptor T-cell therapy, or B-cell-depleting therapy. Active interaction and coordination among healthcare providers, including primary care practitioners, pharmacists, and nursing team members, are needed. Vaccination of household contacts will enhance protection for patients with cancer. Some vaccination and revaccination plans for patients with cancer may be affected by the underlying immune status and the anticancer therapy received. As a result, vaccine strategies may differ from the vaccine recommendations for the general healthy adult population vaccine.Additional information is available at www.asco.org/supportive-care-guidelines.
MeSH
Cells, Microscopy, Electron, Scanning Transmission, Vaccines, Neoplasms, Vaccination, Therapeutics, Infections, Receptors, Antigen, T-Cell
Cited by
- Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies. J Endocrinol Invest, 2025
- Multidisciplinary perspective on a pharmacist-led vaccination clinic in a regional cancer care setting: A qualitative study. Explor Res Clin Soc Pharm, 2025
- Vaccines for preventing infections in adults with solid tumours. Cochrane Database Syst Rev, 2025
- Outcomes and Risk Factors for Influenza and Respiratory Syncytial Virus Lower Respiratory Tract Infections and Mortality in Patients With Lymphoma or Multiple Myeloma: A 7-Year Retrospective Cohort Study. Open Forum Infect Dis, 2025
- Vaccines for preventing infections in adults with haematological malignancies. Cochrane Database Syst Rev, 2025
- Herpes Zoster Vaccination: Insights into Efficacy, Safety, and Guidelines. Vaccines (Basel), 2025
- COVID-19 Vaccine Booster Uptake and Effectiveness Among US Adults With Cancer. JAMA Oncol, 2025
- Immune Checkpoint Inhibitors and Vaccination: Assessing Safety, Efficacy, and Synergistic Potential. Vaccines (Basel), 2024
- Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis. Blood Adv, 2025
- The Influence of Radioligand Therapy on Immunogenicity Against SARS-CoV-2-A Retrospective Single-Arm Cohort Study of Metastatic Prostate Cancer Patients Receiving PSMA Radioligand Therapy. Cancers (Basel), 2025
- Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present. Int J Mol Sci, 2025
- Pertussis Vaccination for Adults: An Updated Guide for Clinicians. Vaccines (Basel), 2025
- Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study. Cancers (Basel), 2025
- Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures. Int J Mol Sci, 2025
- Prevention of herpes zoster in acquired immunocompromised conditions: Review of updates and perspectives from Hong Kong. Hum Vaccin Immunother, 2025
- Infection prevention in the immunocompromised traveler due to conditions other than transplantation: a review. Ther Adv Infect Dis, 2025
- Best Supportive Care for Patients with Chronic Lymphocytic Leukemia: Relevance of Cancer Screening and Immunizations. Cancers (Basel), 2025
- Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma. Curr Oncol, 2025
- Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study. Vaccines (Basel), 2025
- Managing Rheumatoid Arthritis in Older Adults with Cancer. Drugs Aging, 2025